ClinicalTrials.gg
Sign In
Enrolling by invitationNCT07897630Macular EdemaUpdated Oct 27, 2026

Suprachoroidal Bevacizumab Versus Intravitreal Bevacizumab in Diabetic Macular Edema

A Phase 3 interventional study of Bevacizumab and Bevacizumab in Diabetic Macular Edema (DME), sponsored by Khyber Teaching Hospital. Enrolling by invitation at 1 site in Pakistan. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Khyber Teaching Hospital · Phase 3, Interventional, and Treatment

Updated Oct 27, 2026Newly registeredGo to Updates ↓
Phase
Phase 3
Study type
Interventional
Enrollment
60
Allocation
Randomized
Sex
All
01

Study summary

Diabetic macular edema is an eye condition caused by diabetes in which fluid accumulates in the central part of the retina, leading to blurred vision and potentially permanent vision loss. Bevacizumab is a medicine that blocks vascular endothelial growth factor (VEGF), a protein involved in abnormal leakage from blood vessels. It is commonly used as an injection into the eye to treat this condition.

This study aims to compare two methods of delivering bevacizumab in patients with center-involving diabetic macular edema. Participants will be randomly assigned to one of two groups. The first group will receive bevacizumab injections into the vitreous cavity of the eye (intravitreal injection), while the second group will receive injections into the space between the sclera and choroid of the eye (suprachoroidal injection). Both groups will receive injections once a month for three months.

The study will compare changes in vision and central retinal thickness, measured using an eye examination and optical coherence tomography (OCT), from the start of the study to the four-month assessment. The occurrence of treatment-related complications and other adverse events will also be recorded.

The study hypothesis is that suprachoroidal bevacizumab will provide improvements in vision and retinal thickness comparable to intravitreal bevacizumab, with a potentially different safety profile. The findings may help determine whether suprachoroidal delivery is a useful alternative to the established intravitreal route for treating diabetic macular edema.

02

Conditions studied

  • Diabetic Macular Edema (DME)

Browse trials for

Keywords

  • Diabetic Macular Edema
  • intravitreal Bevacizumab
  • Suprachoroidal Bevacizumab
03

In context

Macular Edema

756 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

This study's planned enrollment of 60 is close to the median of 56 across 584 interventional studies indexed under Macular Edema.

Browse Macular Edema studies →

Lead sponsor

Khyber Teaching Hospital is the lead sponsor of 29 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients with centre involving diabetic macular edema on OCT

Exclusion criteria

Exclusion Criteria:

  • PDR, corneal opacity, VMT, previous anti-VEGF treatment, previous PRP
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Suprachoroidal

    Suprachoroidal Bevacizumab Injection

    Drug: Bevacizumab

  • Active comparator
    Intravitreal

    Intravitreal Bevacizumab Injection

    Drug: Bevacizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Central Macular Thickness

    Central Macular Thickness on Optical Coherence Tomography

    Time frame: 3 months

  2. Visual Acuity

    Visual Acuity on LogMAR

    Time frame: 3 months

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Oct 2027, 12 months later.

Of 65 phase 3 interventional studies under Macular Edema, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 38. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2026
First posted
Oct 27, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Oct 2027
CompletionEst.
Dec 2027
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07897630
Lead sponsor
Khyber Teaching Hospital
Responsible party
Imran Ahmad (Associate Professor, Khyber Teaching Hospital) — Principal investigator
First posted
Oct 27, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Oct 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Oct 27, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bevacizumab

Other studies in this condition

Macular Edema →

Other studies from this sponsor

Khyber Teaching Hospital

Start the discussion